Summary
Cardiac adaptation to long-standing arterial hypertension consists of left ventricular hypertrophy (LVH), usually of the concentric type, i.e. an increase in wall thickness at the expense of chamber volume. LVH can no longer be considered only as a simple adaptive myocardial process; it drastically increases the risk of sudden death and cardiovascular morbidity and mortality, irrespective of the levels of arterial pressure. Patients with LVH have more premature ventricular contractions than patients without LVH or normotensive subjects, which indicates that LVH per se increases ventricular ectopic activity.
Antihypertensive therapy should not only lower blood pressure, but also prevent or improve end-organ damage and therefore allow left ventricular mass to regress. Although they lower blood pressure, certain antihypertensive agents such as the thiazide diuretics and arteriolar dilators (hydralazine, minoxidil) have little or even a detrimental effect on LVH. In contrast, other agents such as angiotensin-converting enzyme (ACE) inhibitors, β-blockers, antiadrenergic drugs, and certain calcium antagonists decrease left ventricular mass in parallel with arterial pressure. Recent evidence has shown that a decrease in left ventricular mass induced by certain antihypertensive drugs suppresses ventricular ectopic activity by 85%. In contrast, left ventricular mass and ventricular ectopic activity remain unchanged or may even increase in patients treated with diuretics. It is not known whether the risk of sudden death can be decreased and the ominous prognosis of LVH altered by such specific antihypertensive therapy.
Similar content being viewed by others
References
Amodeo C, Kobrin I, Ventura HO, Messerli FH, Frohlich ED. Immediate and short-term hemodynamic effects of diltiazem in patients with hypertension. Circulation 73: 108–113, 1986
Casale PN, Devereux RB, Milner M, et al. Value of echocardiographic measurement of left ventricular mass in predicting cardiovascular morbid events in hypertensive man. Annals of Internal Medicine 105: 173–178, 1986
Corea L, Bentivoglio M, Verdecchia P. Echocardiographic left ventricular hypertrophy as related to atrial pressure and plasma norepinephrine concentration in arterial hypertension. Reversal by atenolol treatment. Hypertension 5: 837–843, 1983
DeSimone G, Ferrara LA, Lorenzo LD, Lauria R, Fasone ML. Effects of slow-release nifedipine on left ventricular mass and systolic function in mild or moderate hypertension. Current Therapeutic Research 36: 537–544, 1984
Devereux RB, Savage DD, Sachs I, Laragh JH. Relation of hemodynamic load to left ventricular hypertrophy and performance in hypertension. American Journal of Cardiology 51: 171–176, 1983
Devereux RB, Pickering TG, Alderman MH, Chien S, Borer JS, et al. Left ventricular hypertrophy in hypertension. Prevalance and relationship to pathophysiologic variable. Hypertension 9 (Suppl. II): II53–II60, 1987
Drayer JI, Weber MA, Gardin JM, Lipson JL. Effect of long-term antihypertensive therapy on cardiac anatomy in patients with essential hypertension. American Journal of Medicine 75 (Suppl. 3A): 116–120, 1983
Drayer JI, Hall WD, Smith VE, Weber MA, Wollam GI, et al. Effect of the calcium channel blocker nitrendipine on the left ventricular mass in patients with hypertension. Clinical Pharmacology and Therapeutics 40: 679–685, 1986
Dreifus LS. Cardiovascular adaptations in hypertension. Pathophysiology of hypertension. Hypertension Update 2: 50–61, 1984
Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I, et al. Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. American Journal of Cardiology 53: 105–108, 1984
Dunn FG, Ventura HO, Messerli FH, Kobrin I, Frochlich ED. Time course of regression of left ventricular hypertrophy in hypertensive patients treated with atenolol. Circulation 76: 254–258, 1987
Ferrara LA, Fasano ML, DeSimone G, Soro S, Gagliardi R. Antihypertensive and cardiovascular effects of nitrendipine; a controlled study vs placebo. Clinical Pharmacology and Therapeutics 38: 434–438, 1985
Fouad FM, Nakashima Y, Tarazi RC, Salcedo EE. Reversal of left ventricular hypertrophy in hypertensive patients treated by methyldopa. American Journal of Cardiology 49: 795–801, 1982
Fouad FM, Tarazi RC, Liebson PR. Echocardiographic studies of regression of left ventricular hypertrophy in hypertension. Hypertension 9 (Suppl. II): II65–II68, 1987
Frohlich ED. Hemodynamics and other determinants in development of left ventricular hypertrophy. Federation Proceedings 42: 2709–2716, 1983
Frohlich ED. Cardiac hypertrophy in hypertension. New England Journal of Medicine 317:831–833,1987
Frohlich ED, Tarazi RC. Is arterial pressure the sole factor responsible for hypertensive cardiac hypertrophy? American Journal of Cardiology 44: 959–963, 1979
Giles TD, Sander GE, Roffidil LE, Thomas MG, Given MB, et al. Comparative effects of nitrendipine and hydrochlorothiazide on left ventricular function in the treatment of hypertension. First Annual Meeting, American Society of Hypertension, abstract, p. 63A, New York, May 29–30, 1986
Gordon T, Kannel WB. Premature mortality from coronary heart disease. The Framingham Study. Journal of the American Medical Association 215: 1617–1625, 1971
Haugland H, Pederson OM, Foiling M. Changes in ventricular septal thickness in systemic hypertension during treatment with methyldopa and prazosin. American Journal of Cardiology 58: 565–566, 1986
Hill LS, Monaghan M, Richardson PJ. Regression of left ventricular hypertrophy during treatment with antihypertensive agents. British Journal of Clinical Pharmacology 7 (Suppl.): 255S–260S, 1979
Kannel WB. Prevalence and natural history of electrocardiographic left ventricular hypertrophy. American Journal of Medicine 75 (Suppl. 3A): 4–11, 1983
Kannel WB, Gordon T, Offutt D. Left ventricular hypertrophy by electrocardiogram. Prevalence, incidence and mortality in the Framingham study. Annals of Internal Medicine 71: 89–105, 1969
Kannel WB, Levy D, Cupples LA. Left ventricular hypertrophy and risk of cardiac failure. The Framingham study (abstr.). Circulation 74 (Suppl. II): 76, 1986
Kobayashi K, Tarazi RC. Effects of nitrendipine on coronary flow and ventricular hypertrophy in hypertension. Hypertension 5 (Suppl. II): II45–II51, 1983
Levy D, Anderson KM, Savage DD, Balkus SA, Kannel WB, et al. Risk of ventricular arrhythmias in left ventricular hypertrophy; The Framingham Heart Study. American Journal of Cardiology 60: 560–565, 1987
McLeay RAB, Stallard TJ, Watson RDS, Littler WA. The effect of nifedipine on arterial pressure and reflux cardiac control. Circulation 67: 1084–1090, 1983
McLenachan JM, Henderson E, Morris KI, Dargie HJ. Ventricular arrhythmias in patients with hypertensive left ventricular hypertrophy. New England Journal of Medicine 317: 787–792, 1987
MacMahon SW, Wilcken DEL, Macdonald GJ. The effect of weight reduction on left ventricular mass. A randomized controlled trial in young, overweight hypertensive patients. New England Journal of Medicine 314: 334–339, 1986
Massie BM, Hirsch AT, Inouye IK, Tubau JF. Calcium channel blockers as antihypertensive agents. American Journal of Medicine 77: 135–142, 1984
Messerli FH. Clinical determinants and consequences of left ventricular hypertrophy. Proceedings of a symposium: Left ventricular hypertrophy in essential hypertension — mechanisms and therapy. American Journal of Medicine 75(3A):51–56, 1983
Messerli FH, Ventura HO, Elizardi DJ, Dunn FG, Frohlich ED. Hypertension and sudden death. Increased ventricular ectopic activity in left ventricular hypertrophy. American Journal of Medicine 77: 18–22, 1984
Motz W, Ploeger M, Ringsgwandl G, Goeldel N, Garthoff B, et al. Influence of nifedipine on ventricular function and myocardial hypertrophy in spontaneously hypertensive rats. Journal of Cardiovascular Pharmacology 5: 55–61, 1983
Muiesan G, Agabiti-Rosei E, Romanelli G, Muiesan ML, Castellano M, et al. Adrenergic activity and left ventricular function during treatment of essential hypertension with calcium antagonists. American Journal of Cardiology 57:44D–49D, 1986
Pegram BL, Frohlich ED. Cardiovascular adjustment to antiadrenergic agents. American Journal of Medicine 75: 94–99, 1983
Pegram BL, Ishie S, Frohlich ED. Effects of methyldopa, clonidine and hydralazine on cardiac mass and haemodynamics in Wistar Kyoto and spontaneously hypertensive rats. Cardiovascular Research 16: 40–46, 1982
Pfeffer J, Pfeffer M, Fletchner P, Braunwald E. Alterations of cardiac performance in rats with established spontaneous hypertension. American Journal of Cardiology 44:994–998,1979
Rowlands DB, Glover DR, Stallard TJ, Littler WA. Control of blood pressure and reduction of echocardiographically assessed left ventricular mass with once-daily timolol. British Journal of Clinical Pharmacology 14: 89–95, 1982
Savage DD, Drayer JIM, Henry WL, Matthews EC, Ware JH, et al. Echocardiographic assessment of cardiac anatomy and function in hypertensive patients. Circulation 59: 623–632, 1979
Schlant RC, Feiner J, Blumenstein BA, Heymsfield SB, Gilbert CA, et al. Echocardiographic studies of left ventricular anatomy and function before and after treatment of essential hypertension. American Journal of Cardiology 39: 296, 1977
Schmieder RE, Messerli FH, Garavaglia GE, Nunez BD. Cardiovascular effects of verapamil in patients with essential hypertension. Circulation 75: 1030–1036, 1987
Schmieder RE, Sturgill D, Garavaglia GE, Nunez BD, Messerli FH. Improved left ventricular function after regression of myocardial hypertrophy — a paradox? Annals of Internal Medicine, in press
Sen S. Regression of cardiac hypertrophy. Experimental animal model. American Journal of Medicine 75: 87–93, 1983
Sen S, Tarazi RC, Khairallah PA, Bumpus FM. Cardiac hypertrophy in spontaneous hypertensive rats. Circulation Research 35: 775–782, 1974
Tarazi RC. Regression of left ventricular hypertrophy by medical treatment; present status and possible implications. American Journal of Medicine 75: 80–86, 1983
Tarazi RC, Fouad FM. Reversal of cardiac hypertrophy in humans. Hypertension 6 (Suppl. III): III140–III146, 1984
Trimarco B, Ricciardelli B, DeLuca N, Volpe M, Veniero A, et al. Effect of acebutolol on left ventricular hemodynamics and anatomy in systemic hypertension. American Journal of Cardiology 53: 791–796, 1984
Ventura HO, Frohlich ED, Messerli FH, Kobrin I, Kardin MB. Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. American Journal of Cardiology 55: 1023–1026, 1985
Wikstrand J. Diastolic function of the hypertrophied left ventricle. In Messerli FH (Ed.) The heart and hypertension, pp. 131–142, York Medical Books, New York, 1987
Wollam GL, Hall D, Porter VD, Douglas MB, Unger DJ, et al. Time course of regression of left ventricular hypertrophy in treated hypertensive patients. American Journal of Medicine 75:100–110,1983
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Messerli, F.H., Oren, S. & Grossman, E. Left Ventricular Hypertrophy and Antihypertensive Therapy. Drugs 35 (Suppl 5), 27–33 (1988). https://doi.org/10.2165/00003495-198800355-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-198800355-00004